These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3321443)

  • 1. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia.
    Mayer RJ
    Semin Oncol; 1987 Dec; 14(4):384-96. PubMed ID: 3321443
    [No Abstract]   [Full Text] [Related]  

  • 2. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age?
    Bassan R; Barbui T
    Haematologica; 1995; 80(1):82-90. PubMed ID: 7758997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current situation and perspective for treatment of acute myelogenous leukemia in adults].
    Fukushima T; Ueda T
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):295-302. PubMed ID: 9492819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modern strategies in therapy of acute myeloid leukemia (AML) in adulthood. I. Primary treatment of de novo AML].
    Jehn U; Dengler R; Petrides PE
    Internist (Berl); 1996 Jun; 37(6):661-8. PubMed ID: 8768003
    [No Abstract]   [Full Text] [Related]  

  • 5. High dose cytarabine in acute myelogenous leukemia.
    Zittoun R
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():38-42. PubMed ID: 2653516
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of acute myelogenous leukaemia.
    Löwenberg B
    J Intern Med Suppl; 1997; 740():17-22. PubMed ID: 9350177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the road to new drugs in acute myeloid leukemia.
    Löwenberg B
    J Clin Oncol; 2007 Jan; 25(1):1-2. PubMed ID: 17146103
    [No Abstract]   [Full Text] [Related]  

  • 8. [State-of-the-art chemotherapy for acute myeloid leukemia].
    Miyawaki S
    Rinsho Ketsueki; 2012 Jan; 53(1):39-50. PubMed ID: 22374524
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapy of acute myelogenous leukemia. A review.
    Zittoun R
    Leukemia; 1992; 6 Suppl 2():36-8. PubMed ID: 1578939
    [No Abstract]   [Full Text] [Related]  

  • 10. Reappearance of acute myeloid leukemia after almost 23 years of continuous complete remission.
    Lee SH; Abebe L; Paietta E; Einzig A; Wiernik PH
    Am J Hematol; 2009 Jul; 84(7):455-7. PubMed ID: 19507211
    [No Abstract]   [Full Text] [Related]  

  • 11. [Recent advance on chemotherapy of leukemia].
    Nakamura T; Ueda T
    Nihon Naika Gakkai Zasshi; 1994 Sep; 83(9):1531-7. PubMed ID: 7798745
    [No Abstract]   [Full Text] [Related]  

  • 12. High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine.
    Hewlett JS; Chen T; Balcerzak SP; Gutterman JU; Costanzi JJ; Amare M
    Arch Intern Med; 1985 Jun; 145(6):1006-12. PubMed ID: 3890786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More on the treatment of relapsed acute myeloid leukemia.
    Capizzi RL
    Oncology (Williston Park); 1989 Oct; 3(10):72-4. PubMed ID: 2701211
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel strategies for relapsed and refractory acute myeloid leukemia.
    Mato AR; Morgans A; Luger SM
    Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
    Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
    Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
    J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract]   [Full Text] [Related]  

  • 17. Isolated granulocytic sarcoma of the head and neck preceding acute myeloid leukemia.
    Dikbas O; Isik M; Purnak T; Karadag O; Uner A; Altundag K
    Am J Hematol; 2004 May; 76(1):95-6. PubMed ID: 15114610
    [No Abstract]   [Full Text] [Related]  

  • 18. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
    Kalaycio M; Advani A; Pohlman B; Sekeres M; Tripp B; Rybicki L; Sobecks R
    Am J Hematol; 2008 Nov; 83(11):831-4. PubMed ID: 18756545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.